EMFLAZA® (deflazacort) is NOW indicated for the treatment of Duchenne muscular dystrophy in patients 2 YEARS OF AGE AND OLDER.


EMFLAZA® (deflazacort) is a corticosteroid that works through receptors in the body to effectively inhibit inflammation.1-3

Clinical studies demonstrated that, compared to placebo, EMFLAZA:

Delayed the loss of muscle strength of Duchenne patients.4

image of walking patient

Improved the ability to accomplish tasks related to standing, climbing stairs, to run or walk 30 feet.4

image of walking up stairs

Slowed the loss of muscle strength over time.4

Image of flying a toy plane

Clinical studies demonstrate that deflazacort may help decrease the amount of time to complete daily tasks

Deflazacort was assessed against placebo for its effect on the amount of time it took a patient to stand up after lying down, to climb 4 stairs, to walk or run 30 feet, and to propel a wheelchair 30 feet. The tests favored deflazacort to placebo in 3 out of the 4 tests.4,5

Time for supine
to standing

Icon of gowers sign

Time to climb
4 stairs

icon everyday activities

Time to run or
walk 30 feet

Icon of delayed walking
icon of a form

Ready to talk with your healthcare provider about EMFLAZA?

We created a Patient Discussion Guide to make it easier to speak to your healthcare team about Duchenne. The guide includes important questions for you to ask to help you feel prepared and empowered as you establish a treatment plan for your child. Download and print a copy to bring to your next doctor's appointment.

icon of paper

Access Patient Support

Icon of prescription


1. Langhoff E, Olgaard K. In vitro immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells. Br J Clin Pharmacol. 1986;21(2):125-129. 2. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317-333. 3. Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1. 4. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123-2131. 5. EMFLAZA (deflazacort) Prescribing Information. South Plainfield, NJ: PTC Therapeutics, Inc.